Portal de Periódicos da CAPES

Long-term survival of sorafenib-treated FLT3-ITD–positive acute myeloid leukaemia patients relapsing after allogeneic stem cell transplantation

2017; Elsevier BV; Volume: 86; Linguagem: Inglês

10.1016/j.ejca.2017.09.016

1879-0852

Stephan Metzelder, Thomas Schroeder, Michael Lübbert, Markus Ditschkowski, Katharina S. Götze, Sebastian Scholl, Ralf G. Meyer, Peter Dreger, Nadežda Basara, Martin F. Fey, Helmut R. Salih, Anemone Finck, Thomas Pabst, Aristoteles Giagounidis, Guido Kobbe, Ellen Wollmer, Jürgen Finke, Andreas Neubauer, Andreas Burchert,

Myeloproliferative Neoplasms: Diagnosis and Treatment

Fms-like tyrosine kinase 3 internal tandem duplication (FLT3-ITD)-positive acute myeloid leukaemia (AML) relapsing after allogeneic stem cell transplantation (allo-SCT) has a dismal prognosis with limited therapeutic options. FLT3-ITD kinase inhibition is a reasonable but palliative experimental treatment alternative in this situation. Information on long-term outcome is not available.We performed a long-term follow-up analysis of a previously reported cohort of 29 FLT3-ITD-positive AML patients, which were treated in relapse after allo-SCT with sorafenib monotherapy.With a median follow-up of 7.5 years, 6 of 29 patients (21%) are still alive. Excluding one patient who received a second allo-SCT, five patients (17%) achieved sustained complete remissions with sorafenib. Four of these patients are in treatment-free remission for a median of 4.4 years.Sorafenib may enable cure of a proportion of very poor risk FLT3-ITD-positive AML relapsing after allo-SCT.